The use of biochemical markers for diagnosis of the acute coronary syndromes;Primena biohemijskih markera za dijagnostikovanje akutnog koronarnog sindroma

Jugoslovenska Medicinska Biohemija

Volumn 22, Issue 4, 2003, Pages 289-301

  Majkić Singh, Nada ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Acute coronary syndromes; Acute myocardial infarction; Biochemical markers; Cardiac specific proteins; Traditional enzymes

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; CREATINE KINASE; ISOENZYME; LACTATE DEHYDROGENASE; TROPONIN;

CLINICAL PRACTICE; ELECTROPHORESIS; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOLYSIS; HUMAN; LABORATORY DIAGNOSIS; LIVER INJURY; REVIEW; SKELETAL MUSCLE; UNSTABLE ANGINA PECTORIS;

ANGINA;

EID: 0345169722     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0304289M     Document Type: Review

References (70)

1. Wu AHB. Cardiac markers: from enzymes to proteins, diagnosis to prognosis, laboratory to bedside. Ann Clin Lab Sci 1999; 29: 18-23.
2. Karmen A, Wroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 1954; 34: 126-33.
3. Wroblewski F, Ladue JS. Lactic dehydrogenase activity in blood. Proc Soc Exper Biol Med 1955; 90: 210-13.
4. Dreyfus JC, Schapira G, Resnais J, Scebat L. La creatine kinase serique dans le diagnostic de l'infarctus myocardique. Rev Franc Etud Clin et Biol 1960; 5: 386-411.
5. Oliver IT. A spectrophotometric method for the determination of creatine phosphokinase and myokinase. Biochem J 1955; 61: 116-22.
6. Rosalki SB. An improved procedures for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69: 696-705.
7. Hørder M, Elser RC, Gerhardt W, Mathieu M, Sampson EJ. International Federation of Clinical Chemistry, Scientific Division Committee on Enzymes: approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 7. IFCC method for creatine kinase (ATP: creatine N-phosphotransferase, EC 2.7.3.2). Eur J Clin Chem Clin Biochem 1991; 29: 435-56.
8. Roe CR, Limbird LE, Wagner GS, Nerenberg ST. Combined isoenzyme analysis in the diagnosis of myocardial injury: application of electrophoretic methods for the detection and quantitiation of creatine kinase phosphokinase MB isoenzyme. J Lab Clin Med 1972; 80: 577-90.
9. Stone MJ, Willerson JT, Gomez-Sanchez CE, Waterman MR. Radioimmunoassay of myoglobin in human serum. Results in patients with acute myocardial infarction. J Clin Invest 1975; 56: 1334-9.
10. Wu AHB, Laios I, Green S, Gornet TG, Wong SS, Parmaley L, Tonnesen A, Plaisier B, Orlando R. Immunoassays for serum and urine myoglobin: myoglobin clearance assessed as a risk factor for acute renal failure. Clin Chem 1994; 40: 796-802.
11. Chan DW, Taylor E, Frye T, Blitzer RL. Immunoenzymetric assays for creatine kinase MB with subunit-specific monoclonal antibodies compared with an immunochemical method and electrophoresis, Clin Chem 1985; 31: 456-69.
12. Katus HA, Remppis A, Looser S, Hallermeier K, Scheffold T, Kubler W. Enzyme linked immonoassay of cardiac troponin T for the detection of acute miocardial infarction in patients. J Mol Cell Cardiol 1989; 21: 1349-53.
13. Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for the assay of cardiac troponin I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992; 38: 2203-14.
14. World Health Organization Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979; 59: 607-9.
15. Wu AHB. Role of serum biochemical markers in clinical trials. In: Myocardial damage. Early detection by novel biochemical markers. Eds. Kaski JC, Holt DW, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1998, pp. 189-99.
16. Chesebro JH, Knatterud G, Roberts R. et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54.
17. The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Eng J Med 1993; 329: 673-82.
18. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L. The prognostic value of serum troponin T in unstable angina. N Engl J Med 1992; 327: 146-50.
19. Ohman EM, Armstrong PW, Christenson RH, Granger CV, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE, Califf RM, Topol EJ. Risk stratification with admission cardiac troponin T levels in acute myocardial ischemia. N Engl J Med 1996; 335: 1333-41.
20. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Baunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335: 1342-9.
21. Wu AHB, Gornet TG, Harker CC, Chen HL. Role of rapid immunoassays for urgent (»stat«) determination of creatine kinase MB. Clin Chem 1989; 35: 1752-6.
22. Delanghe J, Chapelle JP, el Allaf M, De Buyzere M. Quantitative turbidimetric assay for determining myoglobin evaluated. Ann Clin Biochem 1991; 28: 474-9.
23. Antman EM, Grudzien C, Sacks DB. Evaluation of a rapid bedside assay for detection of serum cardiac troponin T. JAMA 1995; 273: 1279-82.
24. Collinson PO, Thomas S, Siu L, Vasudeva P, Stubbs PJ, Canepa-Anson R. Rapid troponin T measurement in whole blood for detection of myocardial damage. Ann Clin Biochem 1995; 32: 454-8.
25. Brogan GX, Bock JL, McCuskey CF, Hollander JE, Thode H, Gawad Y, Jackowski G. Evaluation of cardiac STATus CK-MB/myoglobin device for rapidly ruling out acute myocardial infarction. Clin Lab Med 1997; 17: 655-68.
26. Apple FS, Christenson RH, Valdes R Jr., Andriak AJ, Berg A, Duh SH, Feng YJ, Jortani SA, Johnson NA, Koplen B, Mascotti K, Wu AHB. Simultaneous rapid measurement of whole blood cardiac troponin 1, creatine kinase MB and myoglobin for detection of myocardial infarction. Clin Chem 1999; 45: 199-205.
27. Collinson PO, John C, Cramp DRG, Canepa-Anson R. Prospective randomised controlled trial of point of care testing with central laboratory testing for cardiac enzyme measurement. (Abstract.) Clin Chem 1998; 44: A69.
28. Sagnella GA. Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. Clin SCi 1998; 95: 519-29.
29. Suzuki T, Yamazaki Y. The role of the natriuretic paptides in the cardiovascular system. Cardiovasc res 2001; 51: 489: 94.
30. Mair J, Hammerar-Lercher A, Puchandorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of hearth failure. Clin Chem Lab Med 2001; 39: 571-88.
31. Chen HH, Burnette JC Jr. Natriuretic peptides in the pathophysiology of congestive hearth failure. Cur Cardiol Rep 2000; 2: 198-205.
32. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002; 87: 97-8.
33. Marian AJ. Genetic risk factors for myocardial infraction. Curr Opin Cardiol 1999; 13: 171-8.
34. Myocardial infraction refefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36: 959-69.
35. Remme WJ, Swedberg K. Task Forece Report. Guidelines for the diagnosis and treatment of chronic hearth failure. Eur Heart J 2001; 22: 1527-60.
36. A report of the Americal College of Cardiology/Americal Heart Association task force on the practice guidelines. Evaluation and management of chronic heart failure in the adult. ACC/AHA Practice Guidelines 2001.
37. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement of healthcare professionals from the Center for Disease Control and Prevention and Americar Heart Association. Circulation 2003; 107: 499-511.
38. Dean KJ. Biochemistry and molecular biology of troponin I and T. In: Cardiac markers. Ed. Wu AHB, Humana, Totowa NJ, 1998, 193-204.
39. Gerhardt W, Ljungdahl L. Troponin T: a sensitive and specific diagnostic and prognostic marker of myocardial damage. Clin Chim Acta 1998; 272: 47-57.
40. Wu AHB. Analytical and clinical evaluation of new diagnostic tests for myocardial damage. Clin Chim Acta 1998; 272: 11-21.
41. ACC/AHA 2002 guideline update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. A report of the American College of Cardiology/Americal Association task force on practice guidelines. Committee on the Management of Patients with Unstable Angina. American College of Cardiology and Americal Heart Association, Inc. 2002; 1-95.
42. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: Is their assay merely a marker of cardiac disease? (opinion article) Clin Chem Lab Med 2002; 40: 752-60.
43. Clerico A, lervasi G, Pilo A. Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr Drug Metab 2000; 1: 85-105.
44. Lott JA, Stang JM. Differential diagnosis of patients with abnormal serum creatine kinase isoenzymes. Clin Lab Med 1989; 9: 627-42.
45. Henderson AR, McQueen MJ, Patten RL, et al. Testing for creatine kinase and creatine kinase-2 in Ontario: reference ranges and assay types. Clin Chem 1992; 38: 1365-70.
46. Smith AF. Separation of tissue and serum creatine kinase isoenzymes on polyacrylamide gel slabs. Clin Chim Acta 1972; 39: 351-9.
47. Wevers RA, Delsing M, Gebbink JAG, Soons JBJ. Postsynthetic changes in creatine kinase isozyme. Clin Chem Acta 1978; 86: 323-7.
48. Secchiero S, Altinier S, Zaninotto M, Lachin M, Plebani M. Evaluation of a new automated system for the determination of CK-MB isoforms. J Clin Lab Anal 1995; 9: 359-65.
49. Suzuki T, Shiraishi T, Tomita K, Totani M, Murachi T. Monoclonal antibody inhibiting creatine kinase MM3 but not isoform MM1. Clin Chem 1990; 36: 153-6.
50. Wu AHB. Creatine kinase isoforms in ischemic hearth disease [Review]. Clin Chem 1989; 35: 7-13.
51. Puelo PR, Guadagno PA, Roberts R, Perryman MB. Sensitive, rapid assay of subforms of creatine kinase MB in plasma. Clin Chem 1989; 35: 1452-5.
52. Puelo PR, Guadagno PA, Roberts R. Early diagnosis of acute myocardial infarction based on an assay for subforms of creatine kinase-MB. Circulation 1990; 82: 759-64.
53. Armbruster DA. The genesis and clinical significance of creatine kinase isoform [Review]. Lab Med 1991; 22: 325-34.
54. Moss DW, Henderson AR. Enzymes. In: Burtis CA, Ashwood ER eds. Tietz Textbook of Clinical Chemistry, 2nd ed. Philadelphia: WB Saunders, 1994, 735-896.
55. Rej R. A. Aminotransferases in disease. Clin Lab Med 1989;9:667-87.
56. Rabitzsch G, Mair J, Lechleitner R, et al. Immuno-enzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41: 966-78.
57. Plebani M, Zaninotto M. Diagnostic strategies using myoglobin measurement in myocardial infarction. Clin Chim Acta 1998; 272: 69-77.
58. Mair J, Puschendorf B, Michel G. Clinical significance of cardiac contractile proteins for the diagnosis of myocardial injury. Adv Clin Chem 1994; 31: 63-98.
59. Apple FS, Sharkey SW, Falafati A, et al. Assessment of left ventricular function using serum cardiac troponin 1 measurements following myocardial infarction. Clin Chim Acta 1998; 272: 59-67.
60. Aranega AE, Reina A, Velez C, Alvarez L, Melguizo C, Arange A. Circulating alpha-actin in angina pectoris. J Mol Cell Cardiol 1993; 25: 15-22.
61. Carville DGM, Dimitrijević N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537-41.
62. Roos W, Eymann E, Symannek M, Duppenthaler J, Wodzig KWH, Pelsers M, Glatz JFC. Monoclonal antibodies to human heart fatty-acid binding protein. J Immunol Meth 1995; 183: 149-153.
63. van Nieuwenhoben FA, Kleine AH, Wodzig KWH, Hermens WT, Kragten HA, Maessen JG, Punt Cd, van Dieijen MP, van der Vusse GJ, Glatz JFC. Discrimination between myocardial and sceletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation 1995; 92: 2848-54.
64. Majkić-Singh, N. Enzimi kod srčanih oboljenja. Klinička enzimologija, AID Praktikum, Beograd, 1993; 228-54.
65. Henderson AR. The use of biochemical markers in ischaemic heart disease: Prefactory remarks. Clin Chim Acta 1998; 272: 3-9.
66. Rabitzsch G, Mair J, Lechleitner P et al. Isoenzyme BB of glycogen phosphorylase b and myocardial infarction (letter). Lancet 1993; 341: 1032-3.
67. Mair J, Artner-Dworzak E, Lechleitner P, Morass B, Smidt J, Wagner I, et al. Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin. Br Heart J 1992; 68: 462-8.
68. Larue C, Calzolari C, Bertinchant JP, Leclercq F, Grolleau R, Pau B. Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction. Clin Chem 1993; 39: 972-9.
69. Majkić-Singh, N. Biohemijski parametri za dijagnostikovanje infarkta miokarda. Infarm 1998; 4: 18-19.
70. Majkić-Singh, N. Novi biohemijski markeri oštećenja miokarda. Arhiv za farmaciju 1998; 5: 577.